top of page
Personalized vaccine may benefit patients with pancreatic cancer
A personalized vaccine was given to patients with pancreatic cancer after surgery, alongside an immunotherapy drug and chemotherapy, and it successfully activated immune cells in half of the patients, potentially delaying the return of the cancer.
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
Personalized vaccine treatment of patients with renal cell carcinoma following surgical resection achieved 100% recurrence-free survival at three years with minimal toxicity. Notably, concurrent administration of immune checkpoint inhibitors did not improve vaccine immunogenicity and efficacy.
Driver mutations targeted personalized peptide vaccines
Post-surgery is ideal for personalized vaccine treatment to reduce residual tumor burden and mitigate cancer-mediated immunosuppression.
Individuelle Heilversuche
The overview on the status of individual healing attempts:
Austria
Germany
Switzerland
Relevant Publications
The following publications have been selected for their relevance to the mechanism of action and potential efficacy of our double-personalized peptide vaccine. These studies provide a scientific foundation for understanding how VERDI vaccine may effectively target and eradicate tumor cells.
Tumor Heterogeneity and Targeted Vaccines
This study discusses the need for developing multiple VERDI vaccines targeting diverse antigens to address tumor heterogeneity.
Personalized Immune Activation
Our technology enables the prediction of T cell-activating epitopes at the individual level, ensuring that VERDI vaccines effectively stimulate patient-specific immune responses.
Importance of Antigen Expression
Quantifying antigen expression in the tumor is crucial to predict the efficacy of VERDI vaccines, increasing the likelihood of tumor eradication.
HLA Allele Expression and Immune Response
HLA allele expression directly impacts antigen presentation and the ability of VERDI vaccines to stimulate effective immune responses.
Real World Evidence for the Efficacy of Personalized Peptide Vaccines
Documenting the successful treatment of patients with personalized peptide vaccines under the “Heilversuch” exemption.
bottom of page